SeqOne Genomics is a French deep-tech company on a mission to make personalized medicine a clinical reality by transforming how genomic data is analyzed and interpreted. Its AI-powered platform sits between raw next-generation sequencing output and the clinical decisions that genetic data is meant to inform, giving molecular laboratories the tools to deliver fast, accurate, and scalable analysis.
The platform automates the complex bioinformatics pipeline required to turn sequencing reads into actionable clinical reports. Using machine learning and curated knowledge, it detects and prioritizes variants, annotates them with clinical relevance, and supports the interpretation workflows that geneticists and molecular pathologists rely on. SeqOne covers a broad range of applications, including oncology, rare and inherited diseases, and, through recent acquisitions, multi-omics and pathogen detection. By streamlining interpretation and standardizing reporting, the company helps labs reduce turnaround times while improving consistency and confidence in results.
SeqOne has built meaningful commercial traction, serving over 140 active laboratory customers across 22 countries and projecting to process more than 110,000 patient analyses in 2025. Its customers include healthcare providers and biopharmaceutical companies, and the company has expanded aggressively, including a strategic acquisition of Congenica to create a broader global leader in AI-powered genomic medicine and to strengthen its presence in the United States.
In May 2025 SeqOne raised a 20 million euro oversubscribed growth round led by new investor Supernova Invest, with continued support from existing major investors Elaia, Omnes, and Merieux Equity Partners. The funding is being used to scale international operations, accelerate growth in the US market, and pursue further strategic acquisitions. By combining clinical-grade bioinformatics with AI-driven interpretation, SeqOne positions itself as core infrastructure for the genomic medicine era.